2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 2010

Anti-Endothelial Cell Antibodies in Pediatric Rheumatic Diseases

Pediatric Rheumatology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2268

Anti-IL6-Receptor Tocilizumab in Graves’ Orbitopathy. Multicenter Study of 46 Patients

Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease

9:00AM-11:00AM: Abstract Number: 2656

Apremilast As Treatment of Refractory Skin Lupus Lesions

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2392

Are Single Nucleotide Polymorphisms in Methotrexate Transporter Proteins Associated with Methotrexate Intolerance in Juvenile Idiopathic Arthritis?

Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis

9:00AM-11:00AM: Abstract Number: 2669

Assessing the Need for Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis in SLE Patients on Immunosuppression

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2149

Assessing the Prevalence of Localized Scleroderma in Childhood Using Dministrative Claims Data from the United States

Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2355

Assessment of Barriers to Exercise Participation in Patients with RA

Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives

9:00AM-11:00AM: Abstract Number: 2657

Assessment of Habitual Physical Activity and Performance during Maximal Exercise Test in Systemic Lupus Erythematosus Patients

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2531

Assessment of Pain Relief with Baricitinib By Treatment History in Patients with Refractory Rheumatoid Arthritis

Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

9:00AM-11:00AM: Abstract Number: 2388

Assessment of Treatment Responses, with Special Reference to Remission Using Juvenile Arthritis Disease Activity Score (JADAS), in the Different Categories of Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis

9:00AM-11:00AM: Abstract Number: 2500

Association between Anti-Citrullinated Protein Antibody Status, Erosive Disease and Healthcare Resource Utilization in Patients with RA

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2457

Association between Biologic Dmards and Weight Change in Patients with Inflammatory Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2689

Association between Small Vessel Disease and Arterial Stiffness in Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2015

Association of Anti-Ro52 Autoantibodies with Interstitial Lung Disease and More Severe Disease Manifestations in Juvenile Idiopathic Inflammatory Myopathies

Pediatric Rheumatology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2569

Association of Enthesitis with Achievement of Normal Quality of Life and Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Adalimumab

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

«Previous Page
1
…
3
4
5
6
7
…
64
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].